NCT06927518 Effects of Receptive Language Intervention vs Individual Therapy for Preschool Children With Autism Spectrum Disorder.
| NCT ID | NCT06927518 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Riphah International University |
| Condition | Autism Spectrum Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-03-20 |
| Primary Completion | 2025-06-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-03-20 with a primary completion date of 2025-06-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by deficits in social communication and social interaction and the presence of restricted, repetitive behaviors. Atypical behaviors, conditioning, and difficulties interacting with others are emblems of Autism spectrum disorder (ASD). Autism spectrum disorder (ASD) frequently affects receptive language skills essential for comprehension and communication. Early intervention is crucial for optimizing language outcomes. This randomized controlled trial (RCT) investigates the comparative efficacy of receptive language intervention (RLI) in group versus individual therapy settings for preschool children with ASD. This study aims to investigate the efficacy of receptive language intervention (RLI) in group versus individual therapy settings for preschool children with Autism Spectrum Disorder (ASD) aged 3-5 years. The study aims to address the knowledge gap regarding optimal delivery methods for receptive language interventions. Twenty preschool children (ages 3-5) with ASD will be randomly assigned to either group (n=10) or individual (n=10) therapy conditions. Outcome measures will assess by Laura Mize Teach Me To Talk receptive language checklist, noted before therapy and after completing 20 sessions post-therapy (after 7 weeks). Statistical analysis was done using SPSS 20. An Independent t-test was utilized to see any difference between groups. The study's findings will inform evidence-based practice, enhancing receptive language skills in preschool children with ASD. The study could give precious perceptivity to clinicians, preceptors, and policymakers, helping them make informed, substantiation-based opinions about the most effective and doable intervention strategies. The expected outcomes include comparable receptive language outcomes between group and individual therapy, identification of setting-specific benefits and challenges, and child characteristics influencing treatment response.
Eligibility Criteria
Inclusion Criteria: * Children aged 3 to 5 years diagnosed with ASD. * Children who are able to attend regular therapy sessions as scheduled in the study (either group or individual therapy). * Both male and female will be included. Exclusion Criteria: * Children with co-occurring severe medical conditions. * Children who have already received intensive speech and language therapy for receptive language skills within the last 6 months. * Children with behavioral issues so severe (e.g., aggression, extreme hyperactivity) that they might disrupt group therapy sessions or be unable to focus in individual therapy.
Contact & Investigator
Syeda Mariam Zahra, MS SLP
PRINCIPAL INVESTIGATOR
Riphah International University
Frequently Asked Questions
Who can join the NCT06927518 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 5 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06927518 currently recruiting?
Yes, NCT06927518 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.
Where is the NCT06927518 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT06927518 clinical trial?
NCT06927518 is sponsored by Riphah International University. The principal investigator is Syeda Mariam Zahra, MS SLP at Riphah International University. The trial plans to enroll 30 participants.